Skip to main content
Caplight Logo









Khondrion

Khondrion

Private
NijmegenHealthcare & Life Scienceshttps://www.khondrion.com/

Last Round

VC Round

May 6, 2025

Total Funding Raised

$3.82M

Company Overview

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

mitochondrial disease therapysonlicromanolprimary mitochondrial diseaseclinical stage biopharmasmall molecule drugbiotechorphan drugrare disease treatmentlate stage clinical trialdrug developmentoral therapeuticredox modulatorPMDmito diseasedrug discovery platformMELAS syndromeMIDD syndrome

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Khondrion Comparables

Compare Khondrion with similar companies based on industry and business-model similarity.

Khondrion comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OMEICOS Therapeutics
86%
Morningside
84%
Tisento Therapeutics
83%

Khondrion Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 6, 2025
VC RoundNov 21, 2024
GrantJul 31, 2018
GrantSep 12, 2016

Key People

Founding team and executive leadership

Jasper Levink

Chief Executive Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 22, 2026

    Grew 33% QoQ from 9 to 12 employees.

  • Dec 24, 2025

    Grew 100% QoQ from 6 to 12 employees.

Khondrion Filings

Explore SEC and related filing metadata, where available.

Khondrion filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Khondrion's valuation, stock price, and market status.

Is Khondrion a public or private company?

Khondrion is a private company.

What is the current stock price of Khondrion?

Khondrion is a private company with no public stock price. No recent secondary market data is available.

How much is Khondrion worth (valuation)?

Valuation information for Khondrion is not publicly available.

Can I buy Khondrion stock?

Khondrion shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Khondrion's last funding round?

Khondrion's most recent funding round was VC Round on May 6, 2025.

Who are the main investors in Khondrion?

Key investors in Khondrion include United Mitochondrial Disease Foundation, Netherlands Enterprise Agency.

Will Khondrion IPO soon?

No public IPO plans have been announced for Khondrion.

How can I track Khondrion secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Khondrion's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNijmegen
Employee Range11
Year Founded2012
Last FundingMay 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?